Initial processing of raw antiserum usually involves affinity capture to isolate immunoglobulins from bulk serum components like albumin and transferrin. The choice between broad-spectrum immunoglobulin capture and antigen-specific isolation fundamentally alters the purity profile of the final polyclonal antibody preparation.

Protein A (derived from Staphylococcus aureus) and Protein G (from Streptococcus species) bind to the Fc region of mammalian IgGs.

This approach isolates the total IgG fraction, capturing both target-specific pAbs and the pre-immune IgG repertoire of the host animal.

Protein A/G resins typically feature high binding capacities (20–40 mg IgG per mL of resin) and high recovery rates (>90%).

Elution is achieved using low-pH buffers, typically 0.1 M glycine-HCl at pH 2.5–3.0. Prompt neutralization with 1 M Tris-HCl (pH 8.5–9.0) is necessary to prevent irreversible denaturation or aggregation of the recovered antibody.

In this workflow, the purified recombinant or synthetic antigen used during the antibody discovery phase is covalently immobilized onto an activated matrix, such as NHS-ester or cyanogen bromide (CNBr)-activated agarose.

Serum is passed through the column, allowing only antigen-reactive pAbs to bind. Non-specific host IgGs pass through in the flow-through fraction.

Antigen matrix preparation requires optimized coupling conditions (pH 7.5–8.5) and adequate ligand density (typically 1–5 mg protein per mL resin). Over-coupling can cause steric hindrance, reducing effective binding capacity.

While antigen affinity purification produces exceptionally high-specificity polyclonal antibody lots, absolute recovery is lower compared to Protein A/G capture, as target-specific antibodies generally account for only 0.5% to 5% of total serum IgG.

High antibody specificity requires the removal of antibodies that bind off-target proteins, conserved protein domains, or fusion tags used during antibody expression. Depletion strategies using negative affinity chromatography are essential to eliminate these unwanted fractions prior to final lot release.

When recombinant immunogens contain fusion tags (e.g., His-tag, GST, or MBP) to assist in antibody expression, host immune responses generate antibodies against both the tag and the target protein. Passing the antiserum over a matrix conjugated solely with the tag protein removes these anti-tag antibodies, leaving target-specific pAbs in the flow-through.

For applications requiring discrimination between closely related isoforms or homologous proteins, counter-selection columns are prepared using the non-target homologous protein.

(i) Antiserum is passed through the counter-selection column under physiological conditions (e.g., PBS at pH 7.4, 150 mM NaCl).

(ii) Cross-reactive pAbs bind to the matrix, while high-specificity clones pass through for subsequent positive selection on the primary target matrix.

Non-specific binding can also stem from electrostatic or hydrophobic interactions with column matrices or sample preparation components. Incorporating non-ionic detergents (e.g., 0.05% Tween-20) or increasing salt concentrations (up to 300–500 mM NaCl) in the wash buffer reduces weak, non-specific retention without disrupting high-affinity antigen-antibody interactions.

Optimizing polyclonal antibody purification requires balancing fraction purity against overall recovery. High-affinity pAbs often bind tightly to the matrix, requiring harsh elution conditions that risk irreversibly denaturing the target immunoglobulins.

Rather than applying a single, harsh low-pH step, applying a descending pH gradient (pH 5.0 to 2.2) allows the separation of pAbs based on binding affinity. Low-affinity antibodies elute at milder pH levels (pH 4.0–4.5), while high-affinity fractions require lower pH (pH 2.2–2.8).

For acid-labile antibodies, non-denaturing elution buffers should be evaluated:

Buffers containing 2.5–3.0 M NaSCN (sodium thiocyanate) or 3.5 M MgCl₂ disrupt hydrophobic interactions at neutral pH.

Inclusion of 10–20% ethylene glycol or propylene glycol in the elution buffer lowers dielectric constants, facilitating gentle release of high-affinity pAbs.

Monitoring purification performance across fractions involves clear analytical metrics:

Immediate post-elution processing, such as rapid buffer exchange via desalting columns or tangential flow filtration (TFF) into a stabilizing storage buffer (PBS, pH 7.4 with 0.02% sodium azide and 20% glycerol), minimizes aggregate formation caused by localized low pH exposure..

The intended downstream assay dictates the stringency and architecture of the purification scheme. Different applications tolerate varying levels of background noise, non-specific IgG, and partial denaturation.

WB applications tolerate minor amounts of non-specific host IgG, provided cross-reactivity with the target species lysates is absent. Protein A/G purification followed by a brief counter-screening against host cell lysates is usually sufficient.

Tissues express abundant Fc receptors and non-target proteins that bind primary antibodies non-specifically. Antigen-affinity purified pAbs are required to avoid background staining. Furthermore, removing anti-species cross-reactivity through host serum absorption columns is recommended for multiplex IHC protocols.

For sandwich ELISA applications, the capture antibody must possess high specificity to prevent non-specific antigen binding on the solid surface. Using a high-affinity antigen-purified pAb for capture ensures low limit-of-detection (LOD) values, while conjugated detection pAbs require rigorous depletion of cross-reactive species to prevent high baseline signals.

Selecting an appropriate purification workflow transforms raw antiserum from a custom polyclonal antibody service into a reliable reagent. Balancing Protein A/G capture, antigen-specific affinity selection, and strategic cross-reactivity depletion enables control over both specificity and yield. By tailoring elution conditions to preserve antibody integrity and adjusting workflows based on the target application, bench researchers can consistently generate high-specificity pAb preparations that deliver reproducible analytical performance.

Alpha Lifetech provides a comprehensive and fully integrated Antibody Discovery Platform to support your custom bispecific antibody development. Utilizing advanced Phage Display Technology and Yeast Display Technology, our platform is designed for the discovery and engineering of high-affinity antibodies across multiple formats, including VHH, Fab, and scFv.

[1] Ascoli CA, Aggeler B. Overlooked benefits of using polyclonal antibodies. Biotechniques. 2018 Sep;65(3):127-136. doi: 10.2144/btn-2018-0065. Epub 2018 Aug 9. PMID: 30089399.
[2] Ferrara F, D'Angelo S, Gaiotto T, Naranjo L, Tian H, Gräslund S, Dobrovetsky E, Hraber P, Lund-Johansen F, Saragozza S, Sblattero D, Kiss C, Bradbury AR. Recombinant renewable polyclonal antibodies. MAbs. 2015;7(1):32-41. doi: 10.4161/19420862.2015.989047. PMID: 25530082; PMCID: PMC4622072.
[3] Moffitt SE, Srivastava A, Schuster-Little N, McEntee CR, March JC, Wang CW, Dotson DR, Goodson HV, Whelan RJ. Polyclonal antibodies targeting defined epitopes on cancer biomarker MUC16. Anal Bioanal Chem. 2026 Aug;418(15):4787-4799. doi: 10.1007/s00216-026-06583-2. Epub 2026 Jun 6. PMID: 42250137; PMCID: PMC13388763.
[4] Treverton J, Arnold DM, Ivanov DG, Ivetic N, Zhang Y, Ali HA, Clare R, Kaltashov IA, Kelton JG, Nazy I. Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia. N Engl J Med. 2025 Sep 4;393(9):879-886. doi: 10.1056/NEJMoa2507175. PMID: 40902162; PMCID: PMC12494375.